Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:41 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,510 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: Stroke
Interventions: Real Ischemic Conditioning, Sham Ischemic Conditioning; Device
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: DNA Repair Disorder, Cockayne Syndrome, Xeroderma Pigmentosum, Trichothiodystrophy
Interventions: Interval History, Physical Examination, ECAB Assessment, Gait Assessment, Specimen Sample Collection; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 6 Months and older
Enrollment: 40 participants
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Bipolar II Disorder, Major Depressive Episode
Interventions: Ziprasidone; Drug
Lead sponsor: The Medical Research Network; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: New York, New York • Plano, Texas

Conditions: Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm
Interventions: Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Tiragolumab; Biological · Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Bethesda, Maryland • Columbus, Ohio

Conditions: Acute Respiratory Infections
Interventions: Quick Defense, Placebo; Dietary Supplement
Lead sponsor: Appalachian State University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Healthy Subjects
Interventions: E2027, E2027 matched placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Acute Respiratory Failure
Interventions: Noninvasive positive pressure ventilation (NIPPV), Vapotherm; Device
Lead sponsor: Vapotherm, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 5
States / cities: Athens, Georgia • Florence, South Carolina • Chattanooga, Tennessee + 2 more

Conditions: SARS-CoV-2, Covid19
Interventions: CoviDx™ Covid-19 Antigen Self-Test; Device
Lead sponsor: Lumos Diagnostics; Industry
Eligibility: 2 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Healthy Subjects
Interventions: Paracetamol fast dissolution suspension, Paracetamol medium dissolution suspension, Paracetamol slow dissolution suspension, Paracetamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years to 50 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Long COVID, Insulin Resistance, Insulin Sensitivity
Interventions: Adipose Tissue Biopsy, Steady State Plasma Glucose (SSPG) Test; Procedure · Diagnostic Test
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Palo Alto, California

Conditions: Acute Myeloid Leukemia, Acute Promyelocytic Leukemia With PML-RARA
Interventions: Computed Tomography, Diffusion Weighted Imaging, Fludeoxyglucose F-18, Gadolinium, Magnetic Resonance Imaging, Positron Emission Tomography, Three-Dimensional Spoiled Gradient MRI; Procedure · Radiation · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Spatial Neglect, Stroke
Interventions: Prism adaptation therapy (PAT) + Electrical stimulation (E-stim), Prism adaptation therapy (PAT) + Sham Stimulator, Gait Training; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Central Vision Loss From Macular Diseases
Interventions: Fixation training; Behavioral
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Placenta Accreta, Blood Pressure, Hemorrhage, Hemorrhage, Postpartum
Interventions: LiDCO CNAP Monitoring Equipment; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiovascular Diseases
Interventions: Web-based Heart Healthy Program; Behavioral
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 21 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Alexandria, Virginia

Conditions: Pain
Interventions: Acetylsalicylic acid (Aspirin, BAY1019036); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Propionic Acidemia, Type I and/or Type II, Methylmalonic Acidemia, Carbamoyl-Phosphate Synthase I Deficiency Disease, Ornithine Carbamoyltransferase Deficiency
Interventions: Carbaglu, Placebo; Drug
Lead sponsor: Mendel Tuchman; Other
Eligibility: 1 Week to 99 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 9
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 6 more

Conditions: Obesity, Morbid Obesity, Diabetes Mellitus, Type 2, Atrial Fibrillation
Interventions: Intermittent Fasting; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV
Interventions: Opt-in or Opt-out testing, Focus Group; Behavioral
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Diagnoses Disease
Interventions: HemoTypeSC; Device
Lead sponsor: Silver Lake Research Corporation; Industry
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Azusa, California

Conditions: Major Depressive Disorder
Interventions: High intensity whole-body infrared heating, Psychotherapy, Questionnaires, Low intensity whole-body infrared heating; Device · Behavioral · Other
Lead sponsor: Charles (Chuck) Raison; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Conscious Sedation, Simple Lacerations Less Than 4 cm, Lumbar Punctures, Minor Incision Drainage of Abscesses Not Requiring Extensive Debridement
Interventions: Nitrous Oxide, Midazolam; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 2 Years to 17 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: SARS-CoV 2
Interventions: Clungene rapid test cassette; Diagnostic Test
Lead sponsor: Fadi Haddad, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 3
States / cities: La Mesa, California • San Diego, California

Conditions: Sternal Wound Infection, Mediastinitis
Interventions: Rapid Sternal Closure System, Conventional wire closure; Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

Motor and Neurophysiological Changes After Ischemic Conditioning in Individuals With Stroke

Natural History Study for DNA Repair Disorders

Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Echinacea and Acute Respiratory Illness

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

High Flow Therapy for the Treatment of Respiratory Failure in the ED

Clinical Evaluation of a COVID-19 Antigen Self-Test (CoviDx™)

A Pharmacokinetic Study Investigating the Rate and Extent of Paracetamol Absorption of Three Experimental Sustained Release Pediatric Suspensions

Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

Spatial-Motor Stroke-Rehab Study

Training to Modify Fixational Eye Movements for Optimizing Visual Performance in People With Central Vision Loss

CNAP vs IABP in Pregnant Women With Placenta Accreta

A Web-Based Cardiovascular Intervention for the Workplace

Bioequivalence of Single Dose Fast Release Aspirin (1000 mg) Tablet Versus Single Dose of Two 500 mg Fast Release Aspirin Tablets

Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia

Lifestyle Intervention Feasibility for Arrhythmia and Symptoms With Intermittent Fasting (LIFE AS IF)

HIV Risk and Prevention in Women

Evaluation of HemoTypeSC as a Novel Rapid Test for Point-of-Care Screening for Sickle-Cell Disease, Hemoglobin C Disease, and Carrier Status in Low-Resource Settings

Enhancing Psychotherapy for Mood Disorders With Whole Body Hyperthermia

A Comparison of Intranasal Midazolam and Nitrous Oxide (N2O) Minimal Sedation for Minor Procedures in a Pediatric Emergency Department

IgG/IgM Antibody Test in Patients Who Have Tested Negative or Positive for COVID-19 With the Standard Method of COVID19 Testing.

Rapid Sternal Closure System (TALON)